Cyclerion Therapeutics, Inc.

CYCN Nasdaq CIK: 0001755237

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation MA
Business Address 301 BINNEY STREET, CAMBRIDGE, MA, 02142
Mailing Address 301 BINNEY STREET, CAMBRIDGE, MA, 02142
Phone 617-621-7722
Fiscal Year End 1231
EIN 831895370

Financial Overview

FY2025 FY

$2.07M
Revenue
-$3.06M
Net Income
$9.98M
Total Assets
$9.09M
Stockholders' Equity
$3.24M
Cash & Equivalents
$-1.11
EPS

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events April 1, 2026 View on SEC
10-K Annual financial report March 31, 2026 View on SEC
8-K Current report of material events February 17, 2026 View on SEC
8-K Current report of material events January 6, 2026 View on SEC
8-K Current report of material events December 1, 2025 View on SEC
10-Q Quarterly financial report November 12, 2025 View on SEC
10-K/A Annual report amendment November 12, 2025 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) October 17, 2025 View on SEC
8-K Current report of material events September 23, 2025 View on SEC
SCHEDULE 13G/A Passive ownership amendment August 14, 2025 View on SEC

Annual Reports

10-K March 31, 2026
  • Transitioned to a lean licensing-focused business model to generate cash.
  • Successfully raised $8.5 million through a private stock sale in March 2025.
View Analysis

Material Events

8-K Acquisition April 1, 2026
High Impact
  • Reverse merger with Korsana Biosciences to pivot into a clinical-stage growth company
  • Secured $380 million in new private funding to fuel Phase 2 clinical trials
View Analysis
8-K Other February 17, 2026
High Impact
  • Positive FDA feedback for lead asset CYC-126, reducing regulatory risk for Phase 2 study design.
  • CYC-126 targets Treatment Resistant Depression (TRD), a significant unmet medical need.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.